These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 5371744)

  • 1. [Changes of the coefficient of peripheral utilization of glucose after venous administration, in hypercholesteremic subjects, after treatment with an antidyslipidemic agent].
    Pasini P
    G Gerontol; 1969 Aug; 17(8):808-16. PubMed ID: 5371744
    [No Abstract]   [Full Text] [Related]  

  • 2. Clofibrate and androsterone effect on serum lipids.
    Orgain ES; Bogdonoff MD; Cain C
    Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of coronary artery disease.
    Br Med J; 1969 Jan; 1(5635):37-8. PubMed ID: 4973519
    [No Abstract]   [Full Text] [Related]  

  • 4. The primary preventiono of ischemic heart disease by means of Atromid-S (clofibrate).
    Oliver MF
    Bull N Y Acad Med; 1968 Aug; 44(8):1021-7. PubMed ID: 4875747
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinico-experimental studies of the influence of Atherolip on lipid and carbohydrate metabolism].
    Hammerl H; Kränzl C; Pichler O; Studlar M
    Med Welt; 1969 Aug; 31():1715-7. PubMed ID: 4895455
    [No Abstract]   [Full Text] [Related]  

  • 6. [Importance of the clofibrat in the treatment of lipid metabolism disorders].
    Laubinger G
    Med Klin; 1968 Jan; 63(4):139-42. PubMed ID: 5670163
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical experiences on the anti-dyslipidemic effect of a new sulfomucopolysaccharide of pancreatic origin].
    Castello S
    Clin Ter; 1971 Aug; 58(4):323-34. PubMed ID: 4258171
    [No Abstract]   [Full Text] [Related]  

  • 8. [Carbohydrate metabolism disorder in ischemic cardiopathies].
    Kleinerman L; Apetrei E; Iliescu M; Cionca H; Constantinescu S; Zătreanu Y
    Med Interna (Bucur); 1970 Sep; 22(9):1071-8. PubMed ID: 5491376
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical contribution to the study of the eulipemic effect of 2 ethyl esters of p-chlorophenoxyisobutyric acid].
    De Michelis S; Paparella P; Seu V
    Clin Ter; 1969 Jul; 50(1):11-26. PubMed ID: 4917326
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
    Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
    [No Abstract]   [Full Text] [Related]  

  • 11. [Action of aluminum bis-parachlorophenoxyisobutyrate (2CPIBA) on various hyperlipoproteinemias: initial results].
    Vastesaeger MM; Peeters H; Blaton V; Vanderveiken F; Vastesaeger E
    Brux Med; 1969 Oct; 49(10):615-29. PubMed ID: 5402903
    [No Abstract]   [Full Text] [Related]  

  • 12. [The therapeutic use of CPIB in pathological increase of the lipid constituents of the blood].
    Cloarec M; Cottet J; Etienne J; Loeper J
    Sem Ther; 1965 Nov; 41(9):499-500. PubMed ID: 5877602
    [No Abstract]   [Full Text] [Related]  

  • 13. [Differentiation and drug therapy of lipemias].
    Schettler G
    Dtsch Med J; 1968 Apr; 19(8):250-8. PubMed ID: 5728720
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of prickly pear (Opuntia robusta) on glucose- and lipid-metabolism in non-diabetics with hyperlipidemia--a pilot study.
    Wolfram RM; Kritz H; Efthimiou Y; Stomatopoulos J; Sinzinger H
    Wien Klin Wochenschr; 2002 Oct; 114(19-20):840-6. PubMed ID: 12503475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypolipemic effect of an association of an extractive mucopolysaccharide and the ethyl ester of the p-chlorophenoxyisobutyric acid].
    Coscelli C; Palmari V; Gnudi A
    Farmaco Prat; 1968 Sep; 23(9):482-90. PubMed ID: 4238440
    [No Abstract]   [Full Text] [Related]  

  • 16. Familial hypercholesterolaemic xanthomatosis and coronary heart disease in a ten-year-old girl.
    Miettinen M
    Ann Paediatr Fenn; 1967; 13(1):35-8. PubMed ID: 6079714
    [No Abstract]   [Full Text] [Related]  

  • 17. [CLINICAL STUDY OF THE ACTION OF BETA-BENZALBUTYRRAMIDE ON THE DYSLIPIDEMIC PATTERN].
    BROGLIA F
    Minerva Med; 1963 Oct; 54():2902-9. PubMed ID: 14105480
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inborn errors of lipid metabolism. Effect of clofibrate on the level of blood lipids of patients with familial hyperlipoproteinemia (type 2, 3 and 4)].
    Sobra J; Heyrovský A; Sulc M; Horáková D
    Cas Lek Cesk; 1969 Aug; 108(36):1065-9. PubMed ID: 5807234
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of hyperlipidemias with para-chlorphenoxyisobutyric acid (Regardin)].
    Bruns W; Jung HD
    Dtsch Gesundheitsw; 1971 Feb; 26(8):359-61. PubMed ID: 5576676
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hypolipemic effects of a new tetralin derivative: compound 13473-Su (Ciba)].
    Ciobanu V; Zălaru MC; Ciocan A; Mihăilescu S
    Stud Cercet Med Interna; 1971; 12(1):67-80. PubMed ID: 5565781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.